Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 710273, 5 pages
http://dx.doi.org/10.1155/2014/710273
Research Article

Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients

1Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Beyazit, 34116 Istanbul, Turkey
2Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA
3Department of Medical Microbiology, Faculty of Medicine, Canakkale Onsekiz Mart University, 17100 Canakkale, Turkey

Received 29 December 2013; Revised 18 February 2014; Accepted 27 February 2014; Published 24 March 2014

Academic Editor: Ketoki Kapila

Copyright © 2014 Cagla Bozkurt-Guzel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Doi, S. Husain, B. A. Potoski, K. R. McCurry, and D. L. Paterson, “Extensively drug-resistant Acinetobacter baumannii,” Emerging Infectious Diseases, vol. 15, no. 6, pp. 980–982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. G. Higgins, C. Dammhayn, M. Hackel, and H. Seifert, “Global spread of carbapenem-resistant Acinetobacter baumannii,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 233–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Cisneros, M. J. Reyes, J. Pachón et al., “Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features,” Clinical Infectious Diseases, vol. 22, no. 6, pp. 1026–1032, 1996. View at Google Scholar · View at Scopus
  4. H. Seifert, A. Strate, and G. Pulverer, “Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality,” Medicine, vol. 74, no. 6, pp. 340–349, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Llaca-Díaz, S. Mendoza-Olazarán, A. Camacho-Ortiz, S. Flores, and E. Garza-González, “One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico,” Chemotherapy, vol. 58, no. 6, pp. 475–481, 2012. View at Publisher · View at Google Scholar
  6. J. Garnacho-Montero and R. Amaya-Villar, “Multiresistant Acinetobacter baumannii infections: epidemiology and management,” Current Opinion in Infectious Diseases, vol. 23, no. 4, pp. 332–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. L. Maragakis and T. M. Perl, “Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options,” Clinical Infectious Diseases, vol. 46, no. 8, pp. 1254–1263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. B. Savage, C. Li, U. Taotafa, B. Ding, and Q. Guan, “Antibacterial properties of cationic steroid antibiotics,” FEMS Microbiology Letters, vol. 217, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. E. B. Hadley and R. E. W. Hancock, “Strategies for the discovery and advancement of novel cationic antimicrobial peptides,” Current Topics in Medicinal Chemistry, vol. 10, no. 18, pp. 1872–1881, 2010. View at Google Scholar · View at Scopus
  10. X.-Z. Lai, Y. Feng, J. Pollard et al., “Ceragenins: cholic acid-based mimics of antimicrobial peptides,” Accounts of Chemical Research, vol. 41, no. 10, pp. 1233–1240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. N. Chin, M. J. Rybak, C. M. Cheung, and P. B. Savage, “Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 4, pp. 1268–1273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. N. Chin, R. N. Jones, H. S. Sader, P. B. Savage, and M. J. Rybak, “Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 2, pp. 365–370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Bozkurt-Guzel, P. B. Savage, and A. A. Gerceker, “In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients,” Chemotherapy, vol. 57, no. 6, pp. 505–510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Leszczyska, A. Namiot, D. E. Fein et al., “Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice,” BMC Microbiology, vol. 9, article 187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Isogai, H. Isogai, K. Takahashi, K. Okumura, and P. B. Savage, “Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria,” Oral Microbiology and Immunology, vol. 24, no. 2, pp. 170–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Howell, J. E. Streib, B. E. Kim et al., “Ceragenins: a class of antiviral compounds to treat orthopox infections,” Journal of Investigative Dermatology, vol. 129, no. 11, pp. 2668–2675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Lara, Y. Feng, J. Bader, P. B. Savage, and R. A. Maldonado, “Anti-trypanosomatid activity of ceragenins,” Journal of Parasitology, vol. 96, no. 3, pp. 638–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Saha, P. B. Savage, and M. Bal, “Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens,” Journal of Applied Microbiology, vol. 105, no. 3, pp. 822–828, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Yahav, L. Farbman, L. Leibovici, and M. Paul, “Colistin: new lessons on an old antibiotic,” Clinical Microbiology and Infection, vol. 18, no. 1, pp. 18–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Guan, C. Li, E. J. Schmidt et al., “Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities,” Organic Letters, vol. 2, no. 18, pp. 2837–2840, 2000. View at Google Scholar · View at Scopus
  21. Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Seventh Edition, Approved Standard M7-A7, CLSI, Wayne, Pa, USA, 2006.
  22. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing: Twenty second Informational Supplement, M100-S22, CLSI, Wayne, Pa, USA, 2012.
  23. National Committee for Clinical Laboratory Standards, Methods for Determining Bactericidal Activity of Antimicrobial Agents—Approved Guideline, M26-A, NCCLS, Wayne, Pa, USA, 1999.
  24. S. K. Pillai, R. C. Moellering Jr., and G. M. Eliopoulos, “Antimicrobial combinations,” in Antibiotics in Laboratory Medicine, V. Lorian, Ed., pp. 365–440, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2005. View at Google Scholar
  25. F. C. Odds, “Synergy, antagonism, and what the chequerboard puts between them,” Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, article 1, 2003. View at Google Scholar · View at Scopus
  26. R. F. Epand, J. E. Pollard, J. O. Wright, P. B. Savage, and R. M. Epand, “Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 9, pp. 3708–3713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Pogue, T. Mann, K. E. Barber, and K. S. Kaye, “Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management,” Expert Review of Anti-infective Therapy, vol. 11, no. 4, pp. 383–393, 2013. View at Publisher · View at Google Scholar
  28. Y. Carmeli, M. Akova, G. Cornaglia et al., “Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 102–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Cai, D. Chai, R. Wang, B. Liang, and N. Bai, “Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 7, pp. 1607–1615, 2012. View at Publisher · View at Google Scholar
  30. M. Giannouli, S. Cuccurullo, V. Crivaro et al., “Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone,” Journal of Clinical Microbiology, vol. 48, no. 4, pp. 1223–1230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ergin, G. Hascelik, and O. K. Eser, “Molecular characterization of oxacillinases and genotyping of invasive Acinetobacter baumannii isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010,” Scandinavian Journal of Infectious Diseases, vol. 45, no. 1, pp. 26–31, 2013. View at Publisher · View at Google Scholar
  32. R. N. Jones, M. A. Pfaller, S. A. Marshall, R. J. Hollis, and W. W. Wilke, “Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood. Stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes,” Diagnostic Microbiology and Infectious Disease, vol. 29, no. 3, pp. 187–192, 1997. View at Publisher · View at Google Scholar · View at Scopus